title: [Weekly paclitaxel therapy for metastatic breast cancer].
abstract: We treated 12 patients with metastatic breast cancer with weekly paclitaxel therapy. Paclitaxel was administrated by 1 hour infusion at a dose of 80 mg/m2 after short premedication every week on an outpatient basis. Administration was continued for 3 weeks followed by 1 week rest. All patients had received prior metastatic chemotherapy, and prior anthracycline therapy was done in 66.7% of the patients. Partial responses were observed in 66.7% of the patients and progressive disease in 33.3%. The response rate was 66.7%. Responses were observed in 62.5% of the patients with prior anthracycline therapy. Grade 3/4 leukopenia and neutropenia occurred in 25% of the patients, respectively, and no grade 3/4 peripheral neuropathy was observed. Dyspnea occurred in 25% of the patients and was grade 3 in 16.7%. Dyspnea is thought to be one of the adverse events requiring caution with weekly paclitaxel administration. Weekly paclitaxel therapy is effective and well tolerated in patients with metastatic breast cancer.
authors.affiliation: Dept. of Surgery, Itami City Hospital.
authors.forename: Ikuo
authors.initials: I
authors.lastname: Kokufu
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Kimura
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Fukuda
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Tokiharu
authors.initials: T
authors.lastname: Yano
authors.forename: Katsumi
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel